Authors
Latest:
FibroGen's Duchenne Muscular Dystrophy Antibody Pamrevlumab Falls Short in Phase 3The study did not meet its primary end point of change from baseline in Performance of the Upper Limb 2.0 score at 1 year.
Latest:
FDA Rejects Duchenne Muscular Dystrophy Drug Golodirsen, Citing Safety ConcernsThe regulatory agency cited 2 concerns in the complete response letter: the risk of infections related to intravenous infusion ports and renal toxicity.
Latest:
Unusual New Onset Seizures in a Healthy, Young Adult MaleA 23-year-old male college student presents with first generalized tonic-clonic seizure followed by episodes of violent psychosis.
Latest:
Advancing the Diagnostic Criteria for Multiple Sclerosis: A New Era of Early Detection and PrecisionWith new revisions of the MS diagnostic criteria being made, clinicians highlighted key updates and the broader implications it has for diagnosis, treatment, and healthcare practices worldwide.
Latest:
Using the Ketogenic Diet to Treat Intractable Epilepsy in Case of Glycine EncephalopathyA boy diagnosed with glycine encephalopathy in the newborn period was initiated on the ketogenic diet at 11 years-old for the treatment of medication refractory epilepsy.
Latest:
Understanding Cerebral Venous Thrombosis: Rare But Sometimes FatalThe prognosis of cerebral venous thrombosis (CVT) is favorable compared with other types of stroke: almost 80% of patients with CVT recover without functional disability. Nevertheless, 5% to 10% of patients die in the acute phase.
Latest:
Understanding Cerebral Venous Thrombosis: Rare But Sometimes FatalThe prognosis of cerebral venous thrombosis (CVT) is favorable compared with other types of stroke: almost 80% of patients with CVT recover without functional disability. Nevertheless, 5% to 10% of patients die in the acute phase.
Latest:
Understanding Cerebral Venous Thrombosis: Rare But Sometimes FatalThe prognosis of cerebral venous thrombosis (CVT) is favorable compared with other types of stroke: almost 80% of patients with CVT recover without functional disability. Nevertheless, 5% to 10% of patients die in the acute phase.
Latest:
Case Report: New Onset Paroxysmal Episodes in an InfantA newborn presents with new onset episodes of lateral gaze deviation with extremity stiffening.
Latest:
Closing the Treatment Gap in Progressive MSNew biomarkers of disease activity may help better vet investigational therapies aimed at slowing the insidious neurodegeneration seen in primary progressive multiple sclerosis.
Latest:
FDA Accepts sNDA for Higher Dosing Regimen of Nusinersen for Spinal Muscular AtrophyIn the phase 2/3 DEVOTE study, a higher dose of nusinersen met its primary end point at 6 months, achieving a statistically significant improvement in motor function among treatment-naïve symptomatic infants with SMA.
Latest:
Cyclic Vomiting, Incontinence in a Young BoyAn 8 year old boy with genetically confirmed neurofibromatosis type 1 presents with first generalized seizure.
